New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 21, 2014
12:55 EDTRCPT, RCPT, NVS, NVS, BIIB, BIIBSummer Street chief scientific officer holds an analyst/industry conference call
Chief Scientific Officer Classen and Biotech Analyst Werther discuss novel drugs for Multiple Sclerosis, including drugs manufactured by RCPT, NVS and BIIB, on an Analyst/Industry conference call to be held on May 21 at 1:30 pm.
News For RCPT;NVS;BIIB From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | all recent news | >>
April 16, 2015
12:35 EDTNVSSandoz receives FDA approval for Glatopa as generic competitor to Copaxone
Sandoz, a Novartis (NVS) company, announced the U.S. approval of Glatopa, the first generic version of Teva's (TEVA) Copaxone 20 mg/ml one-time-daily multiple sclerosis therapy. Glatopa, developed in collaboration with Momenta (MNTA) and produced entirely in the U.S., is indicated for the treatment of patients with relapsing forms of MS, including those who have experienced a first clinical episode and have magnetic resonance imaging features consistent with MS.
09:30 EDTRCPTReceptos announcement a positive surprise, says Leerink
Subscribe for More Information
08:08 EDTRCPTReceptos reports positive results for maintenance period of ozanimod trial
Subscribe for More Information
05:27 EDTNVSAlcon receives FDA approval of AcrySof IQ ReSTOR +2.5 Diopter IOL
Subscribe for More Information
April 15, 2015
07:14 EDTBIIBBiogen volatility flat into new drug data
Biogen overall option implied volatility of 35 compares to its 26-week average of 34 according to Track Data, suggesting non-directional into results as shares rally in the preopen on Phase 2 RENEW study of anti-LINGO-1 in acute optic neuritis clinical data.
April 14, 2015
18:30 EDTBIIBOn The Fly: After Hours Movers
Subscribe for More Information
16:12 EDTBIIBBiogen presents new Anti-LINGO-1 Phase 2 AON data
Subscribe for More Information
11:25 EDTBIIBPTAB declares interference between Forward Pharma and Biogen regarding treatment
Subscribe for More Information
April 13, 2015
16:51 EDTNVSDiplomat Pharmacy to dispense Novartis' JADENU
Diplomat Pharmacy is set to distribute JADENU, a drug recently approved by the U.S. FDA to treat patients with chronic iron overload. JADENU is a new oral formulation of EXJADE for the treatment of chronic iron overload due to blood transfusions in patients age 2 and older, and chronic iron due to NTDT in patients age 10 and older.
05:21 EDTNVSNovartis to present new data that confirms high efficacy of Gilenya
Novartis announced new Gilenya analyses to be presented at the 67th American Academy of Neurology, or AAN, Annual Meeting in Washington, DC, from April 18-25, showing how Novartis is advancing methods assessing the impact of relapsing multiple sclerosis, or RMS, for patients and physicians. Data will show how adding brain shrinkage to an existing tool to assess MS disease activity will give a more precise prediction of the likelihood of future disability progression. Accurate assessment of disease activity is key to guide treatment decisions in RMS. A pooled analysis from the two-year phase III FREEDOMS and FREEDOMS II trials will further confirm Gilenya's high efficacy in previously-treated patients with highly-active RMS in achieving 'no evidence of disease activity' across four key measures: relapses, MRI lesions, brain shrinkage and disability progression. Achieving NEDA4 is especially critical for highly-active RMS patients, who are likely to lose more physical and cognitive functions over time despite being treated.
April 9, 2015
09:25 EDTNVS, BIIBPiper Jaffray pharmaceuticals analysts hold an analyst/industry conference call
Subscribe for More Information
09:17 EDTNVSCourt lifts injunction on sales of generic copy of Spectrum's Fusilev
The U.S. Court of Appeals for the Federal Circuit yesterday issued an order that lifted a temporary injunction put in place March 6 that had blocked Novartis' (NVS) Sandoz unit from selling a generic version of Spectrum Pharmaceuticals' (SPPI) colorectal cancer treatment Fusilev. The appeals court ruled that Spectrum failed to meet the requirements for an injunction pending appeal.
07:27 EDTBIIBBiogen PML death case previously reported, says Deutsche Bank
Subscribe for More Information
07:23 EDTBIIBDoctors report case of fatal PML in patient treated with Tecfidera to NEJM
Subscribe for More Information
April 8, 2015
16:22 EDTNVSOn The Fly: Closing Wrap
Subscribe for More Information
14:23 EDTNVSAdditional bidders for Perrigo could emerge after Mylan offer, says Stifel
Subscribe for More Information
07:24 EDTBIIBNeurotechnology Industry Organization to hold a conference
Subscribe for More Information
April 7, 2015
07:31 EDTBIIBBiogen to present data on neurological disease therapies at AAN meeting
Subscribe for More Information
07:14 EDTNVS, BIIBEyeforpharma to hold a summit
Philadelphia 2015 Commercial Pharma Summit is being held in Philadelphia on April 7-8.
April 6, 2015
08:13 EDTNVSJuno Therapeutics announces patent litigation settlement
Subscribe for More Information
1 | 2 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use